Connect with us

Politics

USDA Releases Report On Status Of Canada’s Hemp Industry

Published

on

The U.S. Department of Agriculture (USDA) has published a report detailing the status of the legal hemp market in neighboring Canada.

The six-page document from Agricultural Attaché Evan Mangino shows that while Canada legalized hemp about 20 years ago—with the U.S. moving to allow the crop under agriculture legislation enacted just last year—producers in both countries are facing similar regulatory challenges.

Of the nearly nearly 5,400 metric tons of hempseed Canada exported last year, more than 70 percent went to the U.S., a figure that will presumably significantly fall going forward with large-scale domestic hemp farms expected to come online across the country by next growing season.

Until recently, hemp farmers in the U.S. said they faced difficulties obtaining hemp seed from Canada, prompting USDA to clarify in April that such imports are permitted under the 2018 Farm Bill.

The report, which was published late last week, also notes that the bulk of hemp cultivated in Canada is used to produce nonviable hempseed, which is added to food products such as “hulled hemp seeds, hemp-based snack foods, hemp oils, hemp protein powders, hemp flour and hemp meal.”

However, because of current regulatory guidelines, hemp and its derivatives cannot currently be used to feed livestock or pets, and CBD cannot be included in health supplements.

“Hemp and hemp products are not currently approved as livestock feed or feed ingredients in Canada,” the attaché  wrote. “In the future, each hemp product intended to be used as a livestock feed single ingredient (such as hemp meal, hemp oil, or hemp seeds) will require separate approval.”

“Currently, the sale of natural health products (NHPs) containing any cannabinoid (including CBD) in Canada is prohibited,” he added. “The Canadian hemp (CHTA) and natural products (CNPA and CHFA) industries continue to advocate for a different regulatory regime for CBD-containing products.”

Canadian veterinary associations have submitted proposals to create a legal pathway that would allow their members to prescribe cannabis compounds like CBD and THC to animals, but at this point, it’s in the research phase. Only one company has been approved to conduct clinical trials on the potential benefits of those ingredients for pets suffering from anxiety.

“Currently, there is no legal pathway for veterinarians in Canada to prescribe cannabis-based medicine for animals or for companies to produce and sell cannabis-based products (including pet food) for pets,” the report states.

Despite federal marijuana legalization in Canada, there’s been a growing call to loosen regulations so that CBD can be sold as a natural health supplement. Currently, there are three ways that CBD can be obtained.

1. Adults can purchase CBD products from a provincially authorized retailer in the same way that THC products can be obtained.

2. Qualified patients can access CBD from federally licensed sellers if they have the required documentation from a health professional.

3. Individuals can also obtain CBD-containing drugs with a prescription if the medication is approved by the country’s health care system.

The U.S. hemp industry has made similar requests to increase legal access to CBD. As USDA develops regulations for hemp, stakeholders and lawmakers have repeatedly implored the Food and Drug Administration (FDA) to develop an alternative regulatory pathway so that hemp-derived CBD products can be added to the food supply or as health supplements.

FDA has said that creating those regulations may require congressional action, or else it could take years for the agency to carve out an exception for CBD.

USDA Says Hemp Farmers Now Qualify For Federal Crop Insurance

Photo by Kimzy Nanney on Unsplash.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Politics

Trinidad And Tobago Lawmakers Approve Marijuana Decriminalization Bill

Published

on

A bill to decriminalize low-level marijuana possession in Trinidad and Tobago was approved by the nation’s House of Representatives on Wednesday.

The recently introduced legislation would remove criminal penalties for possession of up to 30 grams of cannabis. A fixed fine would be imposed for possession of more than 30 but fewer than 60 grams, and it would not impact an individual’s criminal record if the debt is paid.

The proposal would also provide a pathway for expungements of prior cannabis convictions and allow individuals to cultivate up to four plants for personal use. An earlier version specified that they must be male plants, which do not produce flower, but that was amended after lawmakers received public input.

Representatives spent about eight hours debating the bill, and its approval comes after a series of amendments were made in committee. It’s expected to get a vote in the Senate later this month.

There are some provisions that don’t sit well with reform advocates. Specifically, the measure imposes new penalties against possession and distribution of other substances such as LSD, MDMA and ketamine.

The decriminalization bill is one part of a package of marijuana reform proposals that the government brought before Parliament last month. Another piece of legislation, the Cannabis Control Bill, would legalize cannabis for medical, research and religious purposes and establish a regulatory body to approve licenses for marijuana businesses.

That proposal was also discussed during the House session on Wednesday and has been referred to a Joint Select Committee, which is tasked with delivering a report on the bill by February 29, 2020, local journalist Clydeen McDonald reported.

Prime Minister Keith Rowley and Attorney General Faris Al-Rawi have advocated for the policy changes, arguing that legalization and decriminalization will free up law enforcement resources, promote research into the therapeutic potential of cannabis and address racial justice.

“The history of cannabis is rooted in our country and, in fact, in our culture,” Al-Rawi said in his opening remarks. “Cannabis certainly be traced to several ethnic, religious and cultural traditions relevant to Trinidad and Tobago.”

“There are some who say legalize, there are some who say decriminalize, there are some who say do nothing at all, enhance the functions and penalties,” he concluded. “This is not an easy balance to be had, but commonsense tells us that it is by far past the time to make sure that the criminal justice system and the people most at risk are not exposed to the inevitability of just being processed through, after a whole lot of time, exposed to danger for a mere fine.”

The prime minister acknowledged that there’s ongoing debate about the extent to which the country should pursue reform and said “this matter is not a simple matter, but it also not a matter that we need to be frightened of.”

“We’re not going to please everybody by doing this,” he said. “There’s a body of opinion that says it shouldn’t be done at all, people should have to behave themselves. If we don’t do it, it is already an integral part of our societal behavior.”

“There are those who say we shouldn’t do it all, there are those who say we haven’t done enough, we should just legalize it and let the bush grow freely. That is not the position of the majority. The majority view in this country is we should decriminalize but we should not legalize. That may change in the future, I don’t know, but at this time, we decriminalize.”

The vote to advance these bills comes one year after the heads of 19 Caribbean nations announced they would be reviewing marijuana reform proposals. Since then, several regional countries such as St. Kitts have moved to change their country’s cannabis laws.

Thailand Prime Minister Uses Medical Marijuana At Event With Ganja Mascot

Photo courtesy of YouTube/ParlView.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

New Jersey Lawmakers Take First Steps To Put Marijuana Legalization On The 2020 Ballot

Published

on

New Jersey Assembly and Senate committees held hearings on Thursday to discuss a resolution that would put the question of marijuana legalization before voters on the 2020 ballot.

The Oversight, Reform and Federal Relations Committee debated the legislation at a morning hearing, which featured testimony from advocates, stakeholders and opponents, while a companion proposal was later discussed before the Senate Commerce Committee.

Both versions of the resolution have been scheduled for floor action in their respective chambers on Monday.

Separately, legislators in the Assembly Appropriations Committee approved a bill to revise and streamline the expungement process. It has also been listed for floor consideration on Monday.

The proposal to hold a cannabis referendum next November comes after top lawmakers failed to rally enough support to get legalization done legislatively, despite Gov. Phil Murphy (D) actively engaging in negotiations with the Senate and Assembly leaders. One of the main contentions was over how to tax marijuana sales.

“We had hoped to get this done legislatively, but that proved to be too tall of an order,” Assembly Judiciary Chairwoman Annette Quijano (D) said at the start of the Oversight panel hearing. “This is a seismic shift. I do not take that lightly.”

After Senate President Steve Sweeney (D) announced that lawmakers would be approaching legalization through a voter referendum, Murphy said that while he was disappointed, he felt confident New Jersey residents would do what the legislature was unable to accomplish.

In the meantime, the governor said he would work with both chambers to quickly pass more limited legislation decriminalizing cannabis possession.

“We believe prohibition has been a spectacular failure,” Karen O’Keefe, director of state policies for the Marijuana Policy Project told lawmakers on Thursday, adding that regulated markets mitigate public safety and workplace risks that exist under prohibition.

Representatives from ACLU New Jersey, New Jersey CannaBusiness Association, Law Enforcement Action Partnership, Doctors for Cannabis Regulation and Clergy for a New Drug Policy also testified in favor of the measure.

Marijuana reform activist Chris Goldstein argued in his testimony that the language of the proposed ballot question should be revised to emphasize that it would end prohibition and remove criminal penalties associated with cannabis.

In order to put changes to the state’s constitution on the ballot, as would be the case with the legalization referendum, the legislature must approve the proposal with a simple majority in two consecutive years, or once with a three-fifths supermajority.

As NJBiz reported, however, it’s unclear whether the two-year rule means it must be approved in two consecutive calendar years or two legislative sessions. The former would give lawmakers until the end of December to pass it the first time and the latter would give them until Murphy’s State of the State address on January 14, 2020.

Legalizing Marijuana Has Majority Support In Kansas, Poll Finds

Photo courtesy of Philip Steffan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Senators Demand Update From DEA On Marijuana Growing Applications

Published

on

A group of senators are pressing top federal drug and health agencies to provide an update on the status of efforts to increase the number of authorized marijuana manufacturers for research purposes.

A letter from the lawmakers—led by Sen. Elizabeth Warren (D-MA) and addressed to the heads of the Drug Enforcement Administration (DEA), Office of National Drug Control Policy and Department of Health and Human Services—emphasizes the need to expand the supply of research-grade cannabis as more states opt to legalize the plant for medical or recreational use.

It notes that DEA announced more than three years ago that it would begin to approve additional marijuana growers and has since continually delayed that process. While the agency said in August that it is taking steps to make approvals, it argued that the volume of applications received requires it to develop alternative rules before issuing any new licenses.

It made that announcement just before a court deadline mandated that DEA take action in response to a lawsuit brought against it by researchers who had applied for approval to produce cannabis for studies. Because the agency gave the update, however, the suit was dismissed in October.

But the senators aren’t satisfied and wrote that they’re “requesting written guidance on how the DEA will make these licenses available to qualified researchers in a timely manner.”

“While millions of Americans are now lawfully able to use marijuana for recreational and medicinal purposes, there remains limited research on its therapeutic benefits,” the letter, sent on Wednesday, states. “With an ever-growing number of Americans consulting their doctors about marijuana treatment options for conditions such as chronic pain, post-traumatic stress disorder, and terminal illnesses, it is imperative that your agencies make a concerted effort to improve our understanding of cannabis, its potential health benefits, and its health risks.”

The senators also noted that the fact that cannabis remains a Schedule I drug under the Controlled Substances Act “is, in itself, a significant barrier to conducting research.”

“Hampering these research opportunities and discouraging qualified, independent researchers attempting to conduct studies on the benefits of medical marijuana is detrimental to states that wish to thoughtfully implement their own marijuana laws,” they argued. “This research is crucial to developing a thorough understanding of medical marijuana and would be invaluable to doctors, patients, and lawmakers across the nation.”

The letter lists five questions that the agencies are being asked to respond to by January 10.

The group wants the government to provide 1) the status and timeline of application approvals by DEA, 2) details on the existing supply of research-grade cannabis and whether additional varieties are being cultivated, 3) information on any plans to consider rescheduling marijuana, 4) a description of the application process and 5) particulars on any efforts to support research into the therapeutic potential of cannabis, particularly as an alternative to opioid painkillers.

“With millions of American adults having access to recreational marijuana and a growing number seeking the drug for medicinal purposes, the federal government is not providing the necessary leadership and tools in this developing field,” they wrote. “Evidence-based public policy is crucial to ensuring our marijuana laws best serve patients and health care providers.”

“Federal agencies have a unique opportunity to collaborate with one another to expand our nation’s understanding of marijuana’s potential to create safe and effective therapies,” they said.

Sens. Ron Wyden (D-OR), Kamala Harris (D-CA), Kirsten Gillibrand (D-NY), Cory Booker (D-NJ), Jeff Merkley (D-OR), Ed Markey (D-MA) and Jacky Rosen (D-NV) also signed the letter.

Last week, DEA received a separate letter from a bipartisan coalition of House and Senate lawmakers urging them to change policy so that researchers can obtain marijuana from state-legal dispensaries. This would help resolve one problem that scientists have identified in the past, expressing frustration over a lack of diversity in the federal government’s cannabis supply.

One study found that the government’s marijuana is chemically more similar to hemp than what’s available in commercial markets.

DEA will likely find is useful to expand the number of cannabis manufacturers given the quota it released on how much marijuana it plans approve for cultivation in 2020: 3.2 million grams, which represents a 30 percent increase from this year’s quota.

Read the senators’ full marijuana letter below:

Senators Press Feds On Mari… by Marijuana Moment on Scribd

House Democrats Cave To Senate On Two Marijuana And Veterans Measures

Photo courtesy of Brian Shamblen.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!